Instructions for Orlistat

1. All names: Orlistat, Orlistat, Xenical, Xenical

2. Indications:

Orlistat (Orlistat) is indicated for obesity management, including weight loss and weight maintenance when used in conjunction with a low-calorie diet, and may also reduce the risk of weight regain after previous weight loss. Orlistatis suitable for obese patients with initial body mass index (body mass index) ≥30kg/m2 or ≥27kg/m2 and other risk factors (such as hypertension, diabetes, dyslipidemia).

3. Usage and dosage:

The recommended dose of Orlistat is one pill120 mg, three times a day, with each main meal containing fat (within or within 1 hour after a meal). Patients eat a nutritionally balanced, low-calorie diet, with approximately 30% of calories coming from fat. Daily intake of fat, carbohydrates and protein should be spread over three meals. The dose of orlistat can be omitted if meals are missed occasionally or if there is no fat. Because orlistat has been shown to reduce the absorption of certain fat-soluble vitamins and beta-carotene, patients should be advised to take a multivitamin containing fat-soluble vitamins to ensure adequate nutrition.

(1) Combination administration: For patients receiving concomitant treatment with orlistat and cyclosporine, take cyclosporine after3 hours after orlistat. For patients receiving concurrent treatment with orlistat and levothyroxine, patients should be monitored for changes in thyroid function at least 4 hours apart between doses of levothyroxine and orlistat.

Based on fecal fat measurement, the effects of orlistat can be seen 24-48 hours after taking After stopping treatment, fecal fat content usually returns to pre-treatment levels within 48-72 hours.

4. Adverse reactions:

The most common adverse reactions of orlistat are influenza, hypoglycemia, headache, upper respiratory tract infection (cold), rectal greasy spots, abdominal (stomach) pain or discomfort, flatulence (bloating), stool urgency (urgent need to have a bowel movement), fatty or oily stools, gas, liquid stools, oily (stool) passing, and increased bowel movements. The first occurrence of these events occurs within 3 months of starting treatment, and approximately 50% of GI adverse events associated with orlistat treatment last less than 1 week, most last no more than 4 weeks.

5. Storage:

Orlistat Store at 25°C (77°F); tolerances are 15 to 30°C (59 to 86°F). Keep the bottle tightly closed. Orlistat should not be used after the specified expiration date.

6. Taboo:

Orlistat is contraindicated in pregnancy, chronic malabsorption syndrome, cholestasis, and patients with known hypersensitivity to orlistat or any of its components.

7. Mechanism of action:

Orlistat is a reversible inhibitor of gastrointestinal lipase and exerts its therapeutic activity in the gastric and small intestinal lumen by forming covalent bonds with active serine residue sites of gastric and pancreatic lipases. Therefore, the inactivated enzyme is unable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. Since undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive impact on weight control.